查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1712513

全球神經診斷市場 - 2025-2033

Global Neurodiagnostics Market - 2025-2033
出版日期: | 出版商: DataM Intelligence | 英文 198 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

2024 年全球神經診斷市場規模達到 93.5 億美元，預計到 2033 年將達到 211.7 億美元，在 2025-2033 年預測期內的複合年成長率為 9.6%。

神經診斷學是醫學診斷學的一個專門分支，專注於透過使用各種診斷技術和工具來識別、監測和評估神經系統疾病。這些技術主要用於評估神經系統（包括大腦、脊髓和周邊神經）的功能、結構和整體健康狀況。

神經診斷學包括電生理和基於影像的測試，以及在某些情況下的分子診斷，以協助醫療保健提供者診斷與中樞和周圍神經系統相關的疾病。這些疾病包括癲癇、阿茲海默症、帕金森氏症、多發性硬化症、腦瘤、創傷性腦損傷 (TBI) 和睡眠障礙等神經系統疾病。

市場動態：

駕駛員和約束裝置

神經診斷技術的不斷進步極大地推動了神經診斷市場的成長。

不斷進步的技術極大地推動了神經診斷市場的成長，使其能夠進行早期診斷、提高準確性、改善患者治療效果並擴大診斷工具的可及性。這些創新也帶來了具有成本效益的解決方案、改善了患者護理並制定了針對神經系統疾病的個人化治療方案。因此，主要和新興市場參與者正專注於技術先進的神經診斷，這進一步推動了市場的成長

例如，2025 年 4 月，神經診斷開發商 Cadwell Industries 發布了其最新的 Sierra 軟體版本，提供正在申請專利的同步超音波和肌電圖 (EMG)。結合 Sierra Summit 電診斷系統和 Sierra NMUS1 整合超音波，此更新可將電生理資料和超音波成像即時呈現在單一螢幕上。其目的是協助針刺肌電圖、化學去神經支配、神經阻斷和水分離手術。

此外，2024 年 8 月，Natus Medical Incorporated 推出了 autoSCORE，這是第一個能夠自動全面解釋臨床腦電圖的人工智慧模型，其準確性可與醫學專家媲美。 autoSCORE 應用程式有可能改善臨床結果並提高數百萬癲癇患者的護理價值。

神經診斷程序的高成本阻礙了市場成長

神經診斷程序的高成本對市場成長構成了重大障礙，限制了獲得先進診斷工具的機會，尤其是在低收入地區和保險不足的患者中。這些成本阻礙了尖端神經診斷技術的廣泛應用，延誤了許多神經系統疾病患者的診斷和治療。

許多先進的神經診斷技術，如腦電圖、核磁共振成像、CT掃描和PET掃描，都需要昂貴的設備和維護，小型醫院或診所難以負擔。除了設備成本外，這些手術本身也會給患者帶來經濟負擔，特別是那些需要定期進行腦電圖、核磁共振和 CT 掃描等診斷測試的患者。例如，視訊腦電圖監測（保險前）的平均費用為 77,664 美元。

隨著神經診斷市場不斷擴大，解決這些成本挑戰對於提高可及性和可負擔性至關重要。經濟高效的診斷工具、保險改革以及政府對先進神經診斷技術的資助等解決方案對於克服這些障礙並推動未來幾年的市場成長至關重要。

目錄

第1章：市場介紹和範圍

  • 報告目標
  • 報告範圍和定義
  • 報告範圍

第2章：高階主管見解與關鍵要點

  • 市場亮點和戰略要點
  • 主要趨勢和未來預測
  • 按產品類型分類的程式碼片段
  • 按應用程式截取的程式碼片段
  • 最終用戶的程式碼片段
  • 按地區分類

第3章：動態

  • 影響因素
    • 驅動程式
      • 神經診斷技術不斷進步
      • 神經系統疾病盛行率上升
    • 限制
      • 神經診斷程序成本高昂
      • 神經系統疾病的複雜性
    • 機會
      • 與數位治療學的整合
    • 影響分析

第4章：戰略洞察與產業展望

  • 市場領導者和先驅者
    • 新興先鋒和傑出參與者
    • 擁有最大行銷品牌的既定領導者
    • 擁有成熟產品的市場領導者
  • 最新進展與突破
  • 監管和報銷情況
    • 北美洲
    • 歐洲
    • 亞太地區
    • 南美洲
    • 中東和非洲
  • 波特五力分析
  • 供應鏈分析
  • 專利分析
  • SWOT分析
  • 未滿足的需求和差距
  • 市場進入和擴張的推薦策略
  • 情境分析：最佳情況、基本情況和最壞情況預測
  • 定價分析和價格動態

第5章：神經診斷市場（依產品類型）

  • 診斷設備
    • 腦電圖（EEG）
    • 腦磁圖（MEG）
    • MRI（磁振造影）
    • CT掃描（電腦斷層掃描）
    • PET掃描（正子斷層掃描）
    • 睡眠監測設備
    • 肌電圖 (EMG) 設備
    • 多導睡眠圖 (PSG) 設備
    • 其他
  • 試劑、耗材和配件
    • 電極
    • 媒體
    • 緩衝區
    • 抗體
    • 溶劑
    • 其他
  • 軟體和應用程式

第6章：神經診斷市場（按應用）

  • 癲癇
  • 阿茲海默症
  • 帕金森氏症
  • 多發性硬化症
  • 睡眠障礙
  • 頭痛疾病
  • 中風
  • 創傷性腦損傷（TBI）
  • 失智
  • 其他

第7章：神經診斷市場（依最終用戶）

  • 醫院
  • 神經科診所
  • 診斷實驗室
  • 家庭護理設置
  • 其他

第 8 章：神經診斷市場，按區域市場分析和成長機會

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 法國
    • 西班牙
    • 義大利
    • 歐洲其他地區
  • 南美洲
    • 巴西
    • 阿根廷
    • 南美洲其他地區
  • 亞太
    • 中國
    • 印度
    • 日本
    • 韓國
    • 亞太其他地區
  • 中東和非洲

第9章：競爭格局與市場定位

  • 競爭概況和主要市場參與者
  • 市佔率分析與定位矩陣
  • 策略夥伴關係、併購
  • 產品組合和創新的關鍵發展
  • 公司基準化分析

第10章：公司簡介

  • GE HealthCare
    • 公司概況
    • 產品組合
      • 產品描述
      • 產品關鍵績效指標 (KPI)
      • 歷史和預測產品銷售
      • 產品銷售量
    • 財務概覽
      • 公司收入
      • 地區收入佔有率
      • 收入預測
    • 關鍵進展
      • 併購
      • 關鍵產品開發活動
      • 監管部門批准等
    • SWOT分析
  • Siemens Healthineers AG
  • Koninklijke Philips NV
  • FUJIFILM Holdings
  • Thermo Fisher Scientific Inc.
  • Compumedics Limited
  • Natus
  • Stratus
  • Canon Medical Systems USA, Inc.
  • Nihon Kohden Corporation

第 11 章：假設與研究方法

  • 資料收集方法
  • 數據三角測量
  • 預測技術
  • 數據驗證和確認

第 12 章：附錄

簡介目錄
Product Code: MI5095

The global neurodiagnostics market size reached US$ 9.35 billion in 2024 and is expected to reach US$ 21.17 billion by 2033, growing at a CAGR of 9.6% during the forecast period 2025-2033.

Neurodiagnostics refers to a specialized branch of medical diagnostics that focuses on the identification, monitoring, and evaluation of neurological disorders through the use of various diagnostic techniques and tools. These techniques are primarily designed to assess the function, structure, and overall health of the nervous system, including the brain, spinal cord, and peripheral nerves.

Neurodiagnostics encompasses both electrophysiological and imaging-based tests, as well as molecular diagnostics in some cases, to assist healthcare providers in diagnosing conditions related to the central and peripheral nervous systems. These conditions include neurological diseases such as epilepsy, Alzheimer's disease, Parkinson's disease, multiple sclerosis, brain tumors, traumatic brain injuries (TBI), and sleep disorders, among others.

Market Dynamics: Drivers & Restraints

Rising technological advancements in neurodiagnostics are significantly driving the neurodiagnostics market growth.

Rising technological advancements are significantly driving the growth of the neurodiagnostics market by enabling early diagnosis, improving accuracy, enhancing patient outcomes, and expanding accessibility to diagnostic tools. These innovations are also leading to cost-effective solutions, improved patient care, and the development of personalized treatment plans for neurological diseases. Thus, the key and emerging market players are focusing on technologically advanced neurodiagnostics, which are further boosting the growth of the market

For instance, in April 2025, Neurodiagnostics developer Cadwell Industries launched its latest Sierra software release, providing patent-pending, synchronized ultrasound and electromyography (EMG). Combined with the Sierra Summit electrodiagnostic system and Sierra NMUS1 integrated ultrasound, the update brings electrophysiological data and ultrasound imaging together in real time on a single screen. This aims to assist in needle EMG, chemodenervation, nerve block, and hydrodissection procedures.

Additionally, in August 2024, Natus Medical Incorporated launched autoSCORE, the first-of-its-kind artificial intelligence model capable of automatic and comprehensive clinical EEG interpretation, providing accuracy on par with medical experts. The autoSCORE application has the potential to improve clinical outcomes and the value of care for the millions suffering from epilepsy.

High cost of neurodiagnostic procedures hampering the market growth

The high costs associated with neurodiagnostic procedures represent a significant barrier to market growth, limiting access to advanced diagnostic tools, especially in low-income regions and for underinsured patients. These costs hinder the widespread adoption of cutting-edge neurodiagnostic technologies, delaying diagnosis and treatment for many individuals with neurological conditions.

Many of the advanced neurodiagnostic technologies, such as EEG, MRI, CT scans, and PET scans, require expensive equipment and maintenance, making them difficult for smaller hospitals or clinics to afford. In addition to the costs of equipment, the procedures themselves can be financially burdensome for patients, particularly for those requiring regular diagnostic tests such as EEG, MRI, and CT scans. For instance, video EEG monitoring costs an average of $77,664 before insurance.

As the neurodiagnostics market continues to expand, addressing these cost challenges will be crucial for improving accessibility and affordability. Solutions like cost-effective diagnostic tools, insurance reforms, and government funding for advanced neurodiagnostic technologies are essential to overcome these barriers and drive market growth in the coming years.

Segment Analysis

The global neurodiagnostics market is segmented based on product type, application, end-user, and region.

Product Type:

The diagnostic equipment segment is expected to dominate the neurodiagnostics market with the highest market share.

The diagnostic equipment segment is the dominant segment in the neurodiagnostics market due to its crucial role in early detection, accurate diagnosis, and monitoring of neurological diseases. Technologies such as MRI, CT scans, EEG, and PET scans are essential tools for clinicians in diagnosing neurological disorders, including stroke, Alzheimer's disease, Parkinson's disease, epilepsy, and brain tumors.

The continued development of advanced imaging systems and non-invasive diagnostic tools has solidified the diagnostic equipment segment as the leading contributor to the market. Moreover, the novel product launches by key and emerging players by regulatory support are also boosting the segment growth.

For instance, in October 2024, Natus Medical Incorporated submitted an FDA 510(k) premarket notification to the U.S. Food and Drug Administration (FDA) for its Natus point-of-care EEG device. The rapid-deploy decision-support tool is designed to quickly help identify non-convulsive seizures (NCSs) and status epilepticus in acute care environments, supporting rapid intervention and streamlining treatment decisions to improve patient outcomes.

This point-of-care EEG system leverages Natus's leading NeuroWorks software platform to provide a seamless and familiar review experience with remote neurologist collaboration, 24/7 from any web browser. NeuroWorks EEG systems are trusted by more health systems and small practices around the world. With its unparalleled expertise in complex IT environments, Natus will utilize a leading cybersecurity-certified cloud platform to ensure patient data security.

Geographical Analysis

North America is expected to hold a significant position in the global neurodiagnostics market with the highest market share

The North America region is the dominant market for neurodiagnostics, driven by factors such as advanced healthcare infrastructure, high healthcare spending, widespread access to cutting-edge neurodiagnostic technologies, and a high prevalence of neurological diseases. This dominance is also supported by the presence of leading healthcare providers, manufacturers of diagnostic equipment, and ongoing advancements in research and development (R&D).

According to the Alzheimer's Association, nearly 7 million Americans are living with Alzheimer's. By 2050, this number is projected to rise to nearly 13 million. This rising incidence of neurological disorders in North America, including Alzheimer's disease, Parkinson's disease, stroke, epilepsy, and multiple sclerosis, is a significant factor propelling the growth of the neurodiagnostics market. As the prevalence of neurological conditions is increasing, there is a greater need for accurate diagnostic tools.

North America is at the forefront of technological innovation in the neurodiagnostics market, with continuous advancements in diagnostic tools that improve both the accuracy and efficiency of neurological diagnoses. These innovations include AI-powered diagnostic tools and wearable EEG devices, which are transforming how neurological conditions are diagnosed and managed.

For instance, in November 2024, LVIS Corporation launched NeuroMatch Access, an artificial-intelligence (AI)-driven platform for electroencephalogram (EEG) data analysis in the US. The Silicon Valley, US-based company's platform, which received 510(k) clearance from the US Food and Drug Administration (FDA) in May 2023, uses AI to review and interpret EEG signals by removing unwanted artifacts. EEG is used to measure the electrical activity of the brain and can aid in the diagnosis of conditions, including brain damage and epilepsy.

Competitive Landscape

Top companies in the neurodiagnostics market include GE HealthCare, Siemens Healthineers AG, Koninklijke Philips N.V., FUJIFILM Holdings, Thermo Fisher Scientific Inc., Compumedics Limited, Natus, Stratus, Canon Medical Systems USA, Inc., Nihon Kohden Corporation, and among others.

Key Developments

  • In April 2025, Cadwell Industries launched its latest Sierra software release, providing patent-pending, synchronized ultrasound and electromyography (EMG). Combined with the Sierra Summit electrodiagnostic system and Sierra NMUS1 integrated ultrasound, the update brings electrophysiological data and ultrasound imaging together in real time on a single screen. This aims to assist in needle EMG, chemodenervation, nerve block, and hydrodissection procedures.
  • In October 2023, Ceribell, Inc. announced the commercial release of its new AI algorithm, ClarityPro, accompanying the availability of potential additional reimbursement for eligible Medicare patients. ClarityPro is an AI-based software algorithm within the Ceribell EEG system that analyzes EEG waveforms to diagnose electrographic status epilepticus (ESE).
  • In October 2023, BeCareLink introduced a new quantitative and artificial intelligence (AI)-enabled app called BeCare Neuro Link, the new mobile application is intended for the remote, objective, and comprehensive assessment of neurologic patients or those with potential neurologic conditions. It can be used for screening as-of-yet-undiagnosed neurologic conditions as well as monitoring the response to treatment for known neurologic disorders.

Why Purchase the Report?

  • Pipeline & Innovations: Reviews ongoing clinical trials, product pipelines, and forecasts upcoming advancements in medical devices and pharmaceuticals.
  • Product Performance & Market Positioning: Analyze product performance, market positioning, and growth potential to optimize strategies.
  • Real-World Evidence: Integrates patient feedback and data into product development for improved outcomes.
  • Physician Preferences & Health System Impact: Examines healthcare provider behaviors and the impact of health system mergers on adoption strategies.
  • Market Updates & Industry Changes: This covers recent regulatory changes, new policies, and emerging technologies.
  • Competitive Strategies: Analyze competitor strategies, market share, and emerging players.
  • Pricing & Market Access: Reviews pricing models, reimbursement trends, and market access strategies.
  • Market Entry & Expansion: Identifies optimal strategies for entering new markets and partnerships.
  • Regional Growth & Investment: Highlights high-growth regions and investment opportunities.
  • Supply Chain Optimization: Assesses supply chain risks and distribution strategies for efficient product delivery.
  • Sustainability & Regulatory Impact: Focuses on eco-friendly practices and evolving regulations in healthcare.
  • Post-market Surveillance: Uses post-market data to enhance product safety and access.
  • Pharmacoeconomics & Value-Based Pricing: Analyzes the shift to value-based pricing and data-driven decision-making in R&D.

The global neurodiagnostics market report delivers a detailed analysis with 62 key tables, more than 61 visually impactful figures, and 198 pages of expert insights, providing a complete view of the market landscape.

Target Audience 2024

  • Manufacturers: Pharmaceutical, Medical Device, Biotech Companies, Contract Manufacturers, Distributors, Hospitals.
  • Regulatory & Policy: Compliance Officers, Government, Health Economists, Market Access Specialists.
  • Technology & Innovation: AI/Robotics Providers, R&D Professionals, Clinical Trial Managers, Pharmacovigilance Experts.
  • Investors: Healthcare Investors, Venture Fund Investors, Pharma Marketing & Sales.
  • Consulting & Advisory: Healthcare Consultants, Industry Associations, Analysts.
  • Supply Chain: Distribution and Supply Chain Managers.
  • Consumers & Advocacy: Patients, Advocacy Groups, Insurance Companies.
  • Academic & Research: Academic Institutions.

Table of Contents

1. Market Introduction and Scope

  • 1.1. Objectives of the Report
  • 1.2. Report Coverage & Definitions
  • 1.3. Report Scope

2. Executive Insights and Key Takeaways

  • 2.1. Market Highlights and Strategic Takeaways
  • 2.2. Key Trends and Future Projections
  • 2.3. Snippet by Product Type
  • 2.4. Snippet by Application
  • 2.5. Snippet by End-User
  • 2.6. Snippet by Region

3. Dynamics

  • 3.1. Impacting Factors
    • 3.1.1. Drivers
      • 3.1.1.1. Rising Technological Advancements in Neurodiagnostics
      • 3.1.1.2. Rising Prevalence of Neurological Disorders
    • 3.1.2. Restraints
      • 3.1.2.1. High Cost of Neurodiagnostic Procedures
      • 3.1.2.2. Complexity of Neurological Conditions
    • 3.1.3. Opportunity
      • 3.1.3.1. Integration with Digital Therapeutics
    • 3.1.4. Impact Analysis

4. Strategic Insights and Industry Outlook

  • 4.1. Market Leaders and Pioneers
    • 4.1.1. Emerging Pioneers and Prominent Players
    • 4.1.2. Established Leaders with Largest Marketing Brand
    • 4.1.3. Market Leaders with Established Products
  • 4.2. Latest Developments and Breakthroughs
  • 4.3. Regulatory and Reimbursement Landscape
    • 4.3.1. North America
    • 4.3.2. Europe
    • 4.3.3. Asia Pacific
    • 4.3.4. South America
    • 4.3.5. Middle East & Africa
  • 4.4. Porter's Five Forces Analysis
  • 4.5. Supply Chain Analysis
  • 4.6. Patent Analysis
  • 4.7. SWOT Analysis
  • 4.8. Unmet Needs and Gaps
  • 4.9. Recommended Strategies for Market Entry and Expansion
  • 4.10. Scenario Analysis: Best-Case, Base-Case, and Worst-Case Forecasts
  • 4.11. Pricing Analysis and Price Dynamics

5. Neurodiagnostics Market, By Product Type

  • 5.1. Introduction
    • 5.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 5.1.2. Market Attractiveness Index, By Product Type
  • 5.2. Diagnostic Equipment*
    • 5.2.1. Introduction
    • 5.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
    • 5.2.3. Electroencephalogram (EEG)
    • 5.2.4. Magnetoencephalography (MEG)
    • 5.2.5. MRI (Magnetic Resonance Imaging)
    • 5.2.6. CT scan (Computed Tomography)
    • 5.2.7. PET Scan (Positron Emission Tomography)
    • 5.2.8. Sleep Monitoring Devices
    • 5.2.9. Electromyography (EMG) Devices
    • 5.2.10. Polysomnogram (PSG) Devices
    • 5.2.11. Others
  • 5.3. Reagents, Consumables & Accessories
    • 5.3.1. Electrodes
    • 5.3.2. Media
    • 5.3.3. Buffers
    • 5.3.4. Antibodies
    • 5.3.5. Solvents
    • 5.3.6. Others
  • 5.4. Software and Applications

6. Neurodiagnostics Market, By Application

  • 6.1. Introduction
    • 6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 6.1.2. Market Attractiveness Index, By Application
  • 6.2. Epilepsy*
    • 6.2.1. Introduction
    • 6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 6.3. Alzheimer's Disease
  • 6.4. Parkinson's Disease
  • 6.5. Multiple Sclerosis
  • 6.6. Sleep Disorders
  • 6.7. Headache Disorders
  • 6.8. Stroke
  • 6.9. Traumatic Brain Injury (TBI)
  • 6.10. Dementia
  • 6.11. Others

7. Neurodiagnostics Market, By End-User

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 7.1.2. Market Attractiveness Index, By End-User
  • 7.2. Hospitals*
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 7.3. Neurology Clinics
  • 7.4. Diagnostic Laboratories
  • 7.5. Homecare Settings
  • 7.6. Others

8. Neurodiagnostics Market, By Regional Market Analysis and Growth Opportunities

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
    • 8.1.2. Market Attractiveness Index, By Region
  • 8.2. North America
    • 8.2.1. Introduction
    • 8.2.2. Key Region-Specific Dynamics
    • 8.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 8.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 8.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 8.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 8.2.6.1. U.S.
      • 8.2.6.2. Canada
      • 8.2.6.3. Mexico
  • 8.3. Europe
    • 8.3.1. Introduction
    • 8.3.2. Key Region-Specific Dynamics
    • 8.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 8.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 8.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 8.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 8.3.6.1. Germany
      • 8.3.6.2. UK
      • 8.3.6.3. France
      • 8.3.6.4. Spain
      • 8.3.6.5. Italy
      • 8.3.6.6. Rest of Europe
  • 8.4. South America
    • 8.4.1. Introduction
    • 8.4.2. Key Region-Specific Dynamics
    • 8.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 8.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 8.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 8.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 8.4.6.1. Brazil
      • 8.4.6.2. Argentina
      • 8.4.6.3. Rest of South America
  • 8.5. Asia-Pacific
    • 8.5.1. Introduction
    • 8.5.2. Key Region-Specific Dynamics
    • 8.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 8.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 8.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 8.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 8.5.6.1. China
      • 8.5.6.2. India
      • 8.5.6.3. Japan
      • 8.5.6.4. South Korea
      • 8.5.6.5. Rest of Asia-Pacific
  • 8.6. Middle East and Africa
    • 8.6.1. Introduction
    • 8.6.2. Key Region-Specific Dynamics
    • 8.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 8.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 8.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User

9. Competitive Landscape and Market Positioning

  • 9.1. Competitive Overview and Key Market Players
  • 9.2. Market Share Analysis and Positioning Matrix
  • 9.3. Strategic Partnerships, Mergers & Acquisitions
  • 9.4. Key Developments in Product Portfolios and Innovations
  • 9.5. Company Benchmarking

10. Company Profiles

  • 10.1. GE HealthCare*
    • 10.1.1. Company Overview
    • 10.1.2. Product Portfolio
      • 10.1.2.1. Product Description
      • 10.1.2.2. Product Key Performance Indicators (KPIs)
      • 10.1.2.3. Historic and Forecasted Product Sales
      • 10.1.2.4. Product Sales Volume
    • 10.1.3. Financial Overview
      • 10.1.3.1. Company Revenue
      • 10.1.3.2. Geographical Revenue Shares
      • 10.1.3.3. Revenue Forecasts
    • 10.1.4. Key Developments
      • 10.1.4.1. Mergers & Acquisitions
      • 10.1.4.2. Key Product Development Activities
      • 10.1.4.3. Regulatory Approvals, etc.
    • 10.1.5. SWOT Analysis
  • 10.2. Siemens Healthineers AG
  • 10.3. Koninklijke Philips N.V.
  • 10.4. FUJIFILM Holdings
  • 10.5. Thermo Fisher Scientific Inc.
  • 10.6. Compumedics Limited
  • 10.7. Natus
  • 10.8. Stratus
  • 10.9. Canon Medical Systems USA, Inc.
  • 10.10. Nihon Kohden Corporation

LIST NOT EXHAUSTIVE

11. Assumption and Research Methodology

  • 11.1. Data Collection Methods
  • 11.2. Data Triangulation
  • 11.3. Forecasting Techniques
  • 11.4. Data Verification and Validation

12. Appendix

  • 12.1. About Us and Services
  • 12.2. Contact Us